News BMS settles US off-label marketing case for $19.5m BMS illegally promoted schizophrenia drug, says attorney general
News Lundbeck/Otsuka look for new use of mental health drug Companies want new bipolar disorder use for Abilify Maintena.
News Janssen's quarterly schizophrenia drug approved in EU Company hopes new formulation will improve patient outcomes.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.